Merck's Dr Dave Maraldo outlines 3 principles for placing manufacturing capacity and how end-to-end ADC supply chains could shift platform thinking.
|Articles|December 16, 2013
- BioPharm International-12-16-2013
- Volume 2013 eBook
- Issue 1
Strategic Outsourcing in Clinical Development
Author(s)Paul Nelles
Partnering with CDMOs can help bridge the innovation gap.
Advertisement
Partnering with CDMOs can help bridge the innovation gap.
from BioPharm International’s 2013 Innovation Updates and Strategies eBook.
Articles in this issue
almost 13 years ago
Creating Better Medicines through Better Conjugationalmost 13 years ago
Recovering Patent Life with Patent Term Extensionalmost 13 years ago
Leveraging Development Strengths Drives Therapies to Marketalmost 13 years ago
Driving Innovation in Biopharmaceuticalsalmost 13 years ago
Crowdfunding Biopharmaceutical Innovationalmost 13 years ago
Restructuring for Biopharmaceutical SuccessAdvertisement
Related to this article
Donidalorsen sustained a 95% reduction in hereditary angioedema attacks over 2 years, and patients switching from other prophylaxis saw a 71% drop.
A single 240 mg dose of WVE-007 cut visceral fat while preserving lean mass for 1 year, as Activin E fell by up to 88% across INLIGHT dose groups.
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Advertisement
Advertisement
Trending on BioPharm International
1
Zai Lab’s Long-Acting Atopic Dermatitis Bispecific Points to Every-12-Week Dosin
2
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
3
FDA Reportedly Pauses National Priority Voucher Pilot and Pauses CRL Publication
4
Ionis Reports 2-Year Donidalorsen (Dawnzera) Data in HAE Prophylaxis
5